Steven Dudics

Steven Dudics, Ph.D. has a background in science and research. In 2021, they began working as a Scientist II at Deka Biosciences, Inc. Prior to that, they were a Scientist 1 at WindMIL Therapeutics from 2019 to 2021, where they worked on novel cancer immunotherapies utilizing marrow infiltrating lymphocytes (MILs). From 2013 to 2019, they were a Graduate Student at the University of Maryland, Baltimore (UMB).

Steven Dudics, Ph.D. received their Doctor of Philosophy (Ph.D.) in Immunology from the University of Maryland Baltimore in 2019. Prior to that, they obtained a Bachelor's of Science in Pharmaceutical Sciences from The University of Toledo in 2013, with a field of study in Medicinal and Biological Chemistry.